LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

Reports Q4 revenue $$6.278M, consensus $16.58M.” Over the past year, Voyager has significantly advanced our two wholly-owned programs targeting ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

There are at least 38 recognized species of hantavirus across the world, 24 of which cause disease in humans. It’s considered ...

Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the Robotic Radiotherapy ...

Head and neck cancers rank fifth in cancer-related mortality and often begin in the tongue, throat, or neck before metastasizing.

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Prof. Dan Peer & research team. Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells ...